Black Diamond Therapeutics, Inc. (BDTX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Black Diamond Therapeutics announced Q1 2026 financial results on May 7, 2026, providing investors with updated operational and financial performance metrics for the three-month period ended March 31, 2026.
The filing is relatively minimal in disclosure detail, with the substantive information relegated to a press release (Exhibit 99.1) that is explicitly not incorporated by reference into the SEC filing, limiting the official record of material information.
The 8-K was signed by Brent Hatzis-Schoch in his capacity as Chief Operating Officer and General Counsel, indicating active leadership management of regulatory obligations.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-16

Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2025, indicating the company's financial performance for the period.
The company did not provide any additional details or context around the financial results in the 8-K filing, limiting investors' ability to assess the underlying business trends and outlook.
Investors should closely monitor any follow-up communications from the company, such as an earnings press release or conference call, to gain more comprehensive insights into Black Diamond Therapeutics' financial and operational performance.

Other reports for Black Diamond Therapeutics, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.